+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cystic Fibrosis (CF) Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2025-2034

  • PDF Icon

    Report

  • 254 Pages
  • April 2025
  • Region: Global
  • Allied Market Research
  • ID: 6119938
Description Jump to:
The cystic fibrosis (CF) therapeutics market was valued at $12.9 billion in 2024 and is estimated to reach $32.2 billion by 2034, exhibiting a CAGR of 9.6% from 2025 to 2034. Cystic fibrosis is a chronic, inherited disorder that primarily affects the lungs, digestive system, and other organs. Cystic fibrosis (CF) therapeutics includes a range of medical interventions aimed at managing and treating the symptoms and underlying causes of cystic fibrosis. The primary goal of CF therapeutics is to improve the quality of life and extend the lifespan of individuals with the disease. Treatment strategies include the use of CFTR modulators, which target the defective CFTR protein responsible for the disease, thereby improving chloride ion transport and reducing mucus buildup in lungs, pancreas, and gastrointestinal tract. Supportive therapies focus on airway clearance techniques, nutritional support, and infection control to manage symptoms and prevent complications. Despite advancements in treatment, cystic fibrosis remains a life-limiting condition, with lung transplantation considered for end-stage disease.

The cystic fibrosis (CF) therapeutics market growth is driven by advancements in treatment options, rise in patient awareness, and increase in R&D activities. The prevalence of cystic fibrosis has prompted the development of innovative therapies, including modulators and combination treatments targeting the underlying causes of the disease, thereby driving market growth. According to American Lung Association, in 2024, there were about 40,000 people with cystic fibrosis in the U.S. and approximately 100,000 people worldwide. The surge in the patient population boosts demand for effective and long-term therapeutic solutions significantly, which supports market growth.

High adoption of precision medicine and novel therapies, such as CFTR modulators, has revolutionized disease management, improving life expectancy and quality of life for patients. Furthermore, the government initiatives and regulatory support for cystic fibrosis, including orphan drug designations and fast-track approvals, further encourage the development and commercialization of CF therapeutics, thereby driving market growth.Pharmaceutical companies are investing heavily in clinical trials to explore more effective drug formulations and combination therapies, which has enhanced the therapeutic landscape. For instance, in March 2024, the Cystic Fibrosis Foundation's committed an additional $5 million to BiomX to support a Phase 2b clinical trial of BX004, a bacteriophage (phage) therapy targeting chronic Pseudomonas aeruginosa lung infections in CF patients. This investment follows an earlier $5 million funding to BiomX for early-stage safety and tolerability studies.

However, factors such as high cost of treatments, limited access of CF drugs in low-income regions, and challenges in drug development are the factors restrain market growth. The cost of advanced CF therapies, particularly CFTR modulators, remains prohibitively high, which limits their accessibility, especially in developing countries. On the other hand, advancements in genetic research and ongoing innovation in treatment approaches provide lucrative opportunities for market growth. One of the most significant opportunities lies in the continued development of targeted therapies, particularly CFTR modulators, which address the underlying genetic mutations of CF, offering potential for more effective and personalized treatments.

The cystic fibrosis (CF) therapeutics market is segmented into drug class, route of administration, and region. By drug class, the market is segregated into pancreatic enzyme supplements, mucolytics, CFTR modulators, and others. By route of administration, the market is classified into oral and inhaled. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global cystic fibrosis (CF) therapeutics market are Teva Pharmaceutical Industries Ltd., Viatris Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Lupin, Chiesi Farmaceutici S.p.A., Digestive Care, Inc., and GSK plc. Key players operating in the market have adopted product approval, agreement, and clinical trial as their key strategies to expand their product portfolio. For instance, in April 2024, Vertex Pharmaceuticals received the European Commission approval for the label expansion of KALYDECO (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis

transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cystic fibrosis (cf) therapeutics market analysis from 2024 to 2034 to identify the prevailing cystic fibrosis (cf) therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cystic fibrosis (cf) therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cystic fibrosis (cf) therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Drug class

  • Pancreatic Enzyme Supplements
  • Mucolytic
  • CFTR modulators
  • Others

By Route of administration

  • Oral
  • Inhaled

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Viatris Inc.
  • Vertex Pharmaceuticals Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Lupin
  • Digestive Care, Inc.
  • GSK plc.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. High intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growing number of regulatory approvals for cystic fibrosis (CF) therapies
3.4.1.2. Increased research & development investments
3.4.1.3. Health screening and reimbursement support
3.4.1.4. Rise in government initiatives
3.4.2. Restraints
3.4.2.1. Adverse effects assocaited with cystic fibrosis drugs
3.4.2.2. High treatment costs
3.4.3. Opportunities
3.4.3.1. Development of gene therapies
3.4.3.2. Rise in number of pipeline products
CHAPTER 4: CYSTIC FIBROSIS (CF) THERAPEUTICS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Pancreatic Enzyme Supplements
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Mucolytic
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. CFTR modulators
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: CYSTIC FIBROSIS (CF) THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Inhaled
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: CYSTIC FIBROSIS (CF) THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Drug class
6.2.3. Market size and forecast, by Route of administration
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Drug class
6.2.4.1.2. Market size and forecast, by Route of administration
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Drug class
6.2.4.2.2. Market size and forecast, by Route of administration
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Drug class
6.2.4.3.2. Market size and forecast, by Route of administration
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Drug class
6.3.3. Market size and forecast, by Route of administration
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Drug class
6.3.4.1.2. Market size and forecast, by Route of administration
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Drug class
6.3.4.2.2. Market size and forecast, by Route of administration
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Drug class
6.3.4.3.2. Market size and forecast, by Route of administration
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Drug class
6.3.4.4.2. Market size and forecast, by Route of administration
6.3.4.5. Rest of Europe
6.3.4.5.1. Market size and forecast, by Drug class
6.3.4.5.2. Market size and forecast, by Route of administration
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Drug class
6.4.3. Market size and forecast, by Route of administration
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Drug class
6.4.4.1.2. Market size and forecast, by Route of administration
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Drug class
6.4.4.2.2. Market size and forecast, by Route of administration
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Drug class
6.4.4.3.2. Market size and forecast, by Route of administration
6.4.4.4. India
6.4.4.4.1. Market size and forecast, by Drug class
6.4.4.4.2. Market size and forecast, by Route of administration
6.4.4.5. Rest of Asia-Pacific
6.4.4.5.1. Market size and forecast, by Drug class
6.4.4.5.2. Market size and forecast, by Route of administration
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Drug class
6.5.3. Market size and forecast, by Route of administration
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Drug class
6.5.4.1.2. Market size and forecast, by Route of administration
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Drug class
6.5.4.2.2. Market size and forecast, by Route of administration
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Drug class
6.5.4.3.2. Market size and forecast, by Route of administration
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Drug class
6.5.4.4.2. Market size and forecast, by Route of administration
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2024
CHAPTER 8: COMPANY PROFILES
8.1. Teva Pharmaceutical Industries Ltd.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Viatris Inc.
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.3. Vertex Pharmaceuticals Incorporated
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. AbbVie Inc.
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Gilead Sciences, Inc.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. Lupin
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Chiesi Farmaceutici S.p.A.
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Digestive Care, Inc.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.10. GSK plc.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
LIST OF TABLES
Table 01. Global Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 02. Cystic Fibrosis (Cf) Therapeutics Market for Pancreatic Enzyme Supplements, by Region, 2024-2034 ($Million)
Table 03. Cystic Fibrosis (Cf) Therapeutics Market for Mucolytic, by Region, 2024-2034 ($Million)
Table 04. Cystic Fibrosis (Cf) Therapeutics Market for Cftr Modulators, by Region, 2024-2034 ($Million)
Table 05. Cystic Fibrosis (Cf) Therapeutics Market for Others, by Region, 2024-2034 ($Million)
Table 06. Global Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 07. Cystic Fibrosis (Cf) Therapeutics Market for Oral, by Region, 2024-2034 ($Million)
Table 08. Cystic Fibrosis (Cf) Therapeutics Market for Inhaled, by Region, 2024-2034 ($Million)
Table 09. Cystic Fibrosis (Cf) Therapeutics Market, by Region, 2024-2034 ($Million)
Table 10. North America Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 11. North America Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 12. North America Cystic Fibrosis (Cf) Therapeutics Market, by Country, 2024-2034 ($Million)
Table 13. U.S. Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 14. U.S. Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 15. Canada Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 16. Canada Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 17. Mexico Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 18. Mexico Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 19. Europe Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 20. Europe Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 21. Europe Cystic Fibrosis (Cf) Therapeutics Market, by Country, 2024-2034 ($Million)
Table 22. Germany Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 23. Germany Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 24. France Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 25. France Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 26. UK Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 27. UK Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 28. Italy Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 29. Italy Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 30. Rest of Europe Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 31. Rest of Europe Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 32. Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 33. Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 34. Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, by Country, 2024-2034 ($Million)
Table 35. Japan Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 36. Japan Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 37. China Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 38. China Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 39. Australia Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 40. Australia Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 41. India Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 42. India Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 43. Rest of Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 44. Rest of Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 45. LAMEA Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 46. LAMEA Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 47. LAMEA Cystic Fibrosis (Cf) Therapeutics Market, by Country, 2024-2034 ($Million)
Table 48. Brazil Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 49. Brazil Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 50. Saudi Arabia Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 51. Saudi Arabia Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 52. South Africa Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 53. South Africa Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 54. Rest of LAMEA Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024-2034 ($Million)
Table 55. Rest of LAMEA Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024-2034 ($Million)
Table 56. Teva Pharmaceutical Industries Ltd.: Key Executives
Table 57. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 58. Teva Pharmaceutical Industries Ltd.: Product Segments
Table 59. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 60. Viatris Inc.: Key Executives
Table 61. Viatris Inc.: Company Snapshot
Table 62. Viatris Inc.: Product Segments
Table 63. Viatris Inc.: Product Portfolio
Table 64. Vertex Pharmaceuticals Incorporated: Key Executives
Table 65. Vertex Pharmaceuticals Incorporated: Company Snapshot
Table 66. Vertex Pharmaceuticals Incorporated: Product Segments
Table 67. Vertex Pharmaceuticals Incorporated: Product Portfolio
Table 68. Vertex Pharmaceuticals Incorporated: Key Stratergies
Table 69. Abbvie Inc.: Key Executives
Table 70. Abbvie Inc.: Company Snapshot
Table 71. Abbvie Inc.: Product Segments
Table 72. Abbvie Inc.: Product Portfolio
Table 73. F. Hoffmann-La Roche Ltd.: Key Executives
Table 74. F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 75. F. Hoffmann-La Roche Ltd.: Product Segments
Table 76. F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 77. Gilead Sciences, Inc.: Key Executives
Table 78. Gilead Sciences, Inc.: Company Snapshot
Table 79. Gilead Sciences, Inc.: Product Segments
Table 80. Gilead Sciences, Inc.: Product Portfolio
Table 81. Lupin: Key Executives
Table 82. Lupin: Company Snapshot
Table 83. Lupin: Product Segments
Table 84. Lupin: Product Portfolio
Table 85. Lupin: Key Stratergies
Table 86. Chiesi Farmaceutici S.P.A.: Key Executives
Table 87. Chiesi Farmaceutici S.P.A.: Company Snapshot
Table 88. Chiesi Farmaceutici S.P.A.: Product Segments
Table 89. Chiesi Farmaceutici S.P.A.: Product Portfolio
Table 90. Digestive Care, Inc.: Key Executives
Table 91. Digestive Care, Inc.: Company Snapshot
Table 92. Digestive Care, Inc.: Product Segments
Table 93. Digestive Care, Inc.: Product Portfolio
Table 94. Gsk plc.: Key Executives
Table 95. Gsk plc.: Company Snapshot
Table 96. Gsk plc.: Product Segments
Table 97. Gsk plc.: Product Portfolio
LIST OF FIGURES
Figure 01. Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034
Figure 02. Segmentation of Cystic Fibrosis (Cf) Therapeutics Market,2024-2034
Figure 03. Top Impacting Factors in Cystic Fibrosis (Cf) Therapeutics Market (2024 to 2034)
Figure 04. Top Investment Pockets in Cystic Fibrosis (Cf) Therapeutics Market (2025-2034)
Figure 05. Moderate Bargaining Power of Suppliers
Figure 06. Low Threat of New Entrants
Figure 07. Low Threat of Substitutes
Figure 08. High Intensity of Rivalry
Figure 09. Low Bargaining Power of Buyers
Figure 10. Global Cystic Fibrosis (Cf) Therapeutics Market:Drivers, Restraints and Opportunities
Figure 11. Cystic Fibrosis (Cf) Therapeutics Market, by Drug Class, 2024 and 2034(%)
Figure 12. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Pancreatic Enzyme Supplements, by Country 2024 and 2034(%)
Figure 13. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Mucolytic, by Country 2024 and 2034(%)
Figure 14. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Cftr Modulators, by Country 2024 and 2034(%)
Figure 15. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Others, by Country 2024 and 2034(%)
Figure 16. Cystic Fibrosis (Cf) Therapeutics Market, by Route of Administration, 2024 and 2034(%)
Figure 17. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Oral, by Country 2024 and 2034(%)
Figure 18. Comparative Share Analysis of Cystic Fibrosis (Cf) Therapeutics Market for Inhaled, by Country 2024 and 2034(%)
Figure 19. Cystic Fibrosis (Cf) Therapeutics Market by Region, 2024 and 2034(%)
Figure 20. U.S. Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 21. Canada Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 22. Mexico Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 23. Germany Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 24. France Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 25. UK Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 26. Italy Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 27. Rest of Europe Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 28. Japan Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 29. China Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 30. Australia Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 31. India Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 32. Rest of Asia-Pacific Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 33. Brazil Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 34. Saudi Arabia Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 35. South Africa Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 36. Rest of LAMEA Cystic Fibrosis (Cf) Therapeutics Market, 2024-2034 ($Million)
Figure 37. Top Winning Strategies, by Year (2021-2025)
Figure 38. Top Winning Strategies, by Development (2021-2025)
Figure 39. Top Winning Strategies, by Company (2021-2025)
Figure 40. Product Mapping of Top 10 Players
Figure 41. Competitive Dashboard
Figure 42. Competitive Heatmap: Cystic Fibrosis (Cf) Therapeutics Market
Figure 43. Top Player Positioning, 2024
Figure 44. Teva Pharmaceutical Industries Ltd.: Net Revenue, 2022-2024 ($Million)
Figure 45. Teva Pharmaceutical Industries Ltd.: Revenue Share by Segment, 2024 (%)
Figure 46. Viatris Inc.: Net Sales, 2022-2024 ($Million)
Figure 47. Viatris Inc.: Revenue Share by Segment, 2024 (%)
Figure 48. Vertex Pharmaceuticals Incorporated: Net Revenue, 2022-2024 ($Million)
Figure 49. Vertex Pharmaceuticals Incorporated: Revenue Share by Region, 2024 (%)
Figure 50. Abbvie Inc.: Net Revenue, 2022-2024 ($Million)
Figure 51. Abbvie Inc.: Revenue Share by Segment, 2024 (%)
Figure 52. F. Hoffmann-La Roche Ltd.: Sales Revenue, 2022-2024 ($Million)
Figure 53. F. Hoffmann-La Roche Ltd.: Revenue Share by Segment, 2024 (%)
Figure 54. F. Hoffmann-La Roche Ltd.: Revenue Share by Region, 2024 (%)
Figure 55. Gilead Sciences, Inc.: Net Revenue, 2022-2024 ($Million)
Figure 56. Gilead Sciences, Inc.: Revenue Share by Region, 2024 (%)
Figure 57. Lupin: Net Sales, 2022-2024 ($Million)
Figure 58. Lupin: Revenue Share by Segment, 2024 (%)
Figure 59. Lupin: Revenue Share by Region, 2024 (%)
Figure 60. Chiesi Farmaceutici S.P.A.: Net Revenue, 2021-2023 ($Million)
Figure 61. Chiesi Farmaceutici S.P.A.: Revenue Share by Segment, 2023 (%)
Figure 62. Gsk PLC.: Net Revenue, 2022-2024 ($Million)
Figure 63. Gsk PLC.: Revenue Share by Region, 2024 (%)

Companies Mentioned

  • Viatris Inc.
  • Vertex Pharmaceuticals Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Chiesi Farmaceutici S.p.A.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Lupin
  • Digestive Care, Inc.
  • GSK plc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Cystic Fibrosis (CF) Therapeutics Market Report 2025 - Product Image

Cystic Fibrosis (CF) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Cystic Fibrosis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Cystic Fibrosis - Pipeline Insight, 2025 - Product Image

Cystic Fibrosis - Pipeline Insight, 2025

  • Drug Pipelines
  • 100 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Cystic Fibrosis Therapeutics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Pancreatic Enzyme Supplements), Route of Administration (Oral), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Pancreatic Enzyme Supplements), Route of Administration (Oral), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.